Inflammation plays a very important role in the development of non-communicable diseases in the general population, while it remains the leading cause of morbidity and mortality among HIV-positive patients treated with HAART. We aimed to investigate the association between IL-6 and hs-CRP with the components of metabolic syndrome among HIV-positive patients on HAART. We conducted a prospective study among HIV-positive HAART naïve patients. Eighty-six HIV-positive HAART naïve patients and eighty-six HIV-negative subjects to serve as controls at baseline were recruited. The baseline data was taken and recorded before commencing the patients on HAART. Then, the patients were placed on lamivudine, tenofovir and dolutegravir (DTG) HAART regiment and followed up for 24 months. Both serum IL-6 and hs-CRP are higher among HIV-positive patients than healthy control and among patients with and without MetS. Both age, gender, anthropometric and blood pressure FBC and LDL-c show an inverse correlation with the development of MetS at baseline, but not IL-6 and hs-CRP. However, 24 months post-HAART hs-CRP shows a significant correlation with MetS (P= 0.010) but IL-6 has a weak positive correlation with MetS (P= 0.055). In regression model, IL-6 has a strong negative correlation with the development of MetS (r –0.085 p= 0.042), while hs-CRP have a strong positive correlation with the development of MetS (r 0.117 p= 0.008). Interleukin-6 and hs-CRP are found to be highly elevated among patients with HIV than healthy controls, as well as in patients with MetS than those without MetS. Both IL-6 and hs-CRC are associated with the development of MetS among HIV patients on HAART than HAART naïve.